China Biotech Services Holdings Limited Provided earnings Guidance for the year ended December 31, 2019. For the period, the group is expected to record a significant net loss for the 2019 Year as compared to net loss of approximately HKD 69,433,000 recorded for the Corresponding in 2018. The increase in net loss for the 2019 Year was mainly attributable to decrease in revenue due to economic downturn and keen competition; decrease in gross profit due to increase raw material, staff costs and other direct costs in medical laboratory testing and health check services; increase in administrative expenses due to increase in amortisation of intangible assets, research and development costs, legal and professional fee for corporate activities and impairment loss on loan receivables. However, the net loss for the 2019 Year are partially set-off by gain on remeasurement of pre-existing interest in an associate for step acquisition; and gain on fair value change of contingent consideration.